155 filings
Page 2 of 8
8-K
0xkww6
15 Jun 21
Submission of Matters to a Vote of Security Holders
4:03pm
8-K
p82g83853umk8og1
11 May 21
Opiant Pharmaceuticals Announces First Quarter 2021 Financial Results and Corporate Update
4:09pm
8-K
amkb6x2 3sj3pr2r1qpl
13 Apr 21
Other Events
4:10pm
8-K
ujqeq18 nosft1u3
22 Mar 21
Departure of Directors or Certain Officers
4:05pm
8-K
ktd4x
11 Mar 21
Other Events
4:01pm
8-K
apa8b kj79
4 Mar 21
Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
4:07pm
8-K
iem0q wwyw9
28 Jan 21
Departure of Directors or Certain Officers
4:25pm
8-K
pgd 62tlyn0r
21 Jan 21
Departure of Directors or Certain Officers
4:03pm
8-K
dwrtqg
14 Dec 20
Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
4:41pm
8-K
cytziw93
10 Dec 20
Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing
4:09pm
8-K
3nygh
18 Nov 20
Other Events
4:02pm
8-K
ciypowgp20b8b
12 Nov 20
Results of Operations and Financial Condition
4:33pm
8-K
npo9j mau
29 Oct 20
Opiant Pharmaceuticals Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment
4:06pm
8-K
urwll9koc0yk 4zr3m5n
6 Aug 20
Opiant Pharmaceuticals Announces Second Quarter 2020 Financial Results and Corporate Update
4:06pm
8-K
gaz7zeywhvrikqjj2p
28 Jul 20
Entry into a Material Definitive Agreement
4:04pm
8-K
0zvm7ej u4ogr
16 Jun 20
Submission of Matters to a Vote of Security Holders
4:19pm
8-K
jl9xti iv3
8 Jun 20
Opiant Pharmaceuticals Statement on U.S. District Court Decision
7:45am
8-K
7q7sls
12 May 20
Opiant Pharmaceuticals Announces First Quarter 2020 Financial Results and Corporate Update
4:07pm
8-K
zekdwifxci58o aou
25 Mar 20
Regulation FD Disclosure
5:13pm
8-K
o7e6e jjwpor55
20 Mar 20
Departure of Directors or Certain Officers
4:18pm